Regulus Therapeutics Inc. (RGLS)

USD 1.51

(-6.79%)

Market Cap (In USD)

98.9 Million

Revenue (In USD)

-

Net Income (In USD)

-30.03 Million

Avg. Volume

523.02 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.08-3.79
PE
-
EPS
-
Beta Value
1.628
ISIN
US75915K3095
CUSIP
75915K309
CIK
1505512
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joseph P. Hagan M.B.A.
Employee Count
-
Website
https://www.regulusrx.com
Ipo Date
2012-10-09
Details
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.